A vast majority of researchers and specialized tech startup companies have started investing in developing Big Data and Artificial Intelligence (AI) tools to serve the pharmaceutical and medical devices companies, which is believed to transform the clinical trial process. But what exactly is the main outcome of AI?
The buzz around AI in clinical trials is due to its potential as the lynchpin for dramatically improving the probability of success and reducing the timelines.
The answer lies in predictive analysis from available historical data. The main idea of the AI revolution is to bring about “efficient and faster decision making,” provide precision in clinical trials and to bring an effective product from the lab-to-market. The average timeline for a drug molecule to be released from lab-to-market is 9 years with a median development cost of $2 billion. The objective of AI implementation is to eliminate unnecessary repeated clinical evaluations, save costs & time and thereby ensure successful clinical trials.
AI based Clinical Trial transformation process can be divided into three main components:
The first and foremost prerequisite for AI implementation is data mining.
The optimum utilization of patient data will ensure effective patient recruitment and lower dropout rates. Several AI startups such as “DEEP6” and “antidote” have invested in developing patient trial matching software.
Artificial intelligence is now being used for predicting cancer treatment type based on the combination of genes in the clinical trials right in the planning stage.
The Salesforce Einstein platform can act as a smart assistant which can be integrated into a CTMS. The Einstein Voice and Einstein predictive builder can help leverage artificial Intelligence in clinical trials in the following ways:
Investment in AI and Big Data will certainly improve the clinical trial process. However, initial investments on tools and technologies need to be taken into consideration. Further, market experience with AI tools will bring down the costs and time-to-market of the drug. How AI can transform the drug discovery process, and make the above statement true – Only time will tell.
https://www.himss.org/library/ehr
https://www.himss.org/electronic-medical-records
https://www.ijclinicaltrials.com/index.php/ijct/article/download/125/94
https://www.jpmorgan.com/commercial-banking/insights/ai-transform-clinical-trials
https://healthcareweekly.com/artificial-intelligence-clinical-trials/
http://www.iagrp.com/views/3_types_artificial_intelligence_clinical_research/
https://www.salesforce.com/in/products/einstein/overview/
https://www.salesforce.com/video/193342/
https://www.salesforce.com/products/einstein-analytics/products/einstein-discovery/
https://www.salesforce.com/products/einstein/einstein-voice/